Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
General Rheumatology
How do you approach the use of prolonged corticosteroid therapy in patients at high risk of bleeding?
(Such as those on long term anticoagulation)
Related Questions
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?
What is your approach to a patient on immunosuppressants with an outpatient cutaneous MRSA infection or to a MRSA carrier?
What aspects of a patients clinical presentation would make you consider a diagnostic challenge of anakinra to assess for an underlying auto-inflammatory syndrome in hospitalized patient with fever of unknown origin?
Does synovial biopsy provide diagnostic value in undifferentiated inflammatory arthritis?
How will you adjust your approach to steroid taper in patients with PMR also on sarilumab?
Are serologies reliable in a patient undergoing workup for autoimmune disease who is receiving IVIG for a different indication?
How do you approach dosing of anakinra in MAS?
At what point would you consider anticoagulation in a pregnant patient with lupus nephritis and non-nephrotic range proteinuria?
What else do you consider in the differential diagnosis for pulmonary-renal syndromes if there is low clinical and serologic evidence of AAV, Goodpasture's or other rheumatologic disease (SLE, RA, APS, Scleroderma)?
Is polymyalgia rheumatica associated with increased toxicity for lung SBRT?